CancerPPD

This page gives details of Query peptides and provides facility to browse the same in CancerPPD database. Please wait while data is being retrieved. For more information see HELP page.

ID	PMID	SEQUENCE	NAME	LENGTH	ACTIVITY
1025	14499271	FLPLLAGLAANFLPTIICKISYKC	GGN6	24	IC₅₀=4.91 µg/ml
1026	14499271	LLAGLAANFLPTIICKISYKC	PTP1	21	IC₅₀=>100 µg/ml
1027	14499271	FAGLAANFLPTIICKISYKC	PTP2	20	IC₅₀=>100 µg/ml
1028	14499271	FLKLLKKLAAKFLPTIICKISYKC	PTP4	24	IC₅₀=18.18 µg/ml
1029	14499271	FLKLLKKLAAKLF	PTP5	13	Not Available
1030	14499271	FLKLLKKLAAKLF	PTP6	13	IC₅₀=15.07 µg/ml
1031	14499271	FLGALFKALSKLL	PTP7	13	IC₅₀=5.4 µg/ml
1032	14499271	FLKLLAGLLKNFA	PTP8	13	IC₅₀=30.79 µg/ml
1674	22641352	LLRHVVKILEKYL	Temporin-La	13	52.77 Inhibition ratio at 50 µg/ml
1675	22641352	LLRHVVKILSKYL	Temporin-Las	13	59.37 Inhibition ratio at 50 µg/ml
1676	22641352	RGDLLRHVVKILEKYL	RGD-La	16	70.39 Inhibition ratio at 50 µg/ml
1677	22641352	RGDLLRHVVKILSKYL	RGD-Las	16	86.175 Inhibition ratio at 50 µg/ml
1682	22641352	LLRHVVKILEKYL	Temporin-La	13	50.90 Inhibition ratio at 50 µg/ml
1683	22641352	LLRHVVKILSKYL	Temporin-Las	13	55.98 Inhibition ratio at 50 µg/ml
1684	22641352	RGDLLRHVVKILEKYL	RGD-La	16	60.22 Inhibition ratio at 50 µg/ml
1685	22641352	RGDLLRHVVKILSKYL	RGD-Las	16	73.07 Inhibition ratio at 50 µg/ml
1694	22641352	LLRHVVKILEKYL	Temporin-La	13	37.22 Inhibition ratio at 50 µg/ml
1695	22641352	LLRHVVKILSKYL	Temporin-Las	13	37.00 Inhibition ratio at 50 µg/ml
1696	22641352	RGDLLRHVVKILEKYL	RGD-La	16	36.25 Inhibition ratio at 50 µg/ml
1697	22641352	RGDLLRHVVKILSKYL	RGD-Las	16	38.13 Inhibition ratio at 50 µg/ml
2886	20383464	MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG	Ceropin	63	91.8% Cell viability at 12.5 µM
2887	20383464	MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG	Ceropin	63	84.1% Cell viability at 25 µM
2888	20383464	MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG	Ceropin	63	76.3% Cell viability at 50 µM
2889	20383464	MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG	Ceropin	63	71.5 % Cell viability at 75 µM
2890	20383464	MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG	Ceropin	63	54.2 % Cell viability at 100 µM
2891	20383464	MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG	Ceropin	63	87.3 % Cell viability at 25 µM
2892	20383464	MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG	Ceropin	63	75.6 % Cell viability at 50 µM
2893	20383464	MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG	Ceropin	63	62.8 % Cell viability at 75 µM
2894	20383464	MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG	Ceropin	63	54.3 % Cell viability at 100 µM
2895	20383464	MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG	Ceropin	63	48.6 % Cell viability at 100 µM
2896	20383464	MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG	Ceropin	63	72.1 % Cell viability at 12.5 µM
2897	20383464	MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG	Ceropin	63	63.3 % Cell viability at 25 µM
2898	20383464	MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG	Ceropin	63	49.7 % Cell viability at 50 µM
2899	20383464	MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG	Ceropin	63	41.1 % Cell viability at 75 µM
2900	20383464	MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG	Ceropin	63	35.2 % Cell viability at 100 µM
3826	23034893	MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVY PSDYNGKTVGPDEKIQINSCGRENASSGTEGSFDIVDPNDGNKTIRHFYW ECPWGSKRNTWTPSGSNTKWMVEWSGQNLDSGALGTITVDVLRKGN	AAD (or Aa-Pri1)	145	At 2.5 µM concentration,decrease in cell vibility= 35%
4036	12631273, 9266696	GLFDVIKKVASVIGGL	Citropin 1.1	16	IC₅₀= 5 M
4045	12631273, 9266696	glfdvikkvasviggl	Citropin 1.1D	16	IC₅₀= 5 M
4054	12631273, 9266696	GLFAVIKKVASVIGGL	3	16	IC₅₀= > 1 µM
4063	12631273, 9266696	GLFDVIKAVASVIGGL	5	16	IC₅₀= >100 µM
4072	12631273, 9266696	GLFDVIKKVAAVIGGL	7	16	IC₅₀= 5 M
4081	12631273, 9266696	GLFDVIKKVASVIKGL	11	16	IC₅₀= 5 M
4090	12631273, 9266696	GLFDVIKKVASVIKKL	13	16	IC₅₀= 5 M
4099	12631273, 9266696	GLFDVIAKVASVIKKL	14	16	IC₅₀= 5 M
4108	12631273, 9266696	GLFAVIKKVASVIKGL	15	16	IC₅₀= 5 M
4117	12631273, 9266696	GLFAVIKKVASVIKKL	16	16	IC₅₀= 5 M
4126	12631273, 9266696	GLFAVIKKVAAVIKKL	17	16	IC₅₀= 5 M
4135	12631273, 9266696	GLFAVIKKVAAVIRRL	18	16	IC₅₀= >10 µM
4144	12631273, 9266696	GLFAVIKKVAKVIKKL	19	16	IC₅₀= 5 M
4153	12631273, 9266696	GLFKVIKKVASVIGGL	22	16	IC₅₀= >10 µM
4162	12631273, 9266696	GLFKVIKKVAKVIKKL	23	16	IC₅₀= >10 µM
4171	12631273, 9266696	LGGIVSAVKKIVDFLG	retro	16	IC₅₀= >10 µM
4223	16091933	YSL	Tyroserleutide	3	39.0% cytotoxic at 0.1 µg/ml
4224	16091933	YSL	Tyroserleutide	3	20.8% cytotoxic at 1 µg/ml
4225	16091933	YSL	Tyroserleutide	3	33.8% cytotoxic at 10 µg/ml
4226	16091933	YSL	Tyroserleutide	3	35.6% cytotoxic at 100 µg/ml
5055	24714081	TKPRKTKPRKTKPRKTKPR	T Peptide	19	69.6% maximum inhibitory rate at 8 mg/kg

CancerPPD :Database of Anticancer peptides and Proteins

Browse Result page of CancerPPD